Latest News

A phase 4 trial underway in the U.S. is examining whether patients with CIDP on stable IVIg can transition to efgartigimod PH20 SC within one week of their last infusion, without requiring documented disease worsening first.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 12, 2026.

Pariceract missed meeting the primary and key secondary efficacy end points in the phase 2b ACTIVATE trial, leading to the discontinuation of its development for GBA1-associated Parkinson disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jessica Ailani, MD. [LISTEN TIME: 17 minutes]

Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.

Romy Hoque, MD, Professor of Neurology at Emory University, previews the 2026 SLEEP Annual Meeting, highlighting key themes across neurodegeneration, hypersomnolence, sleep apnea, and the growing role of GLP-1 receptor agonists in sleep medicine.

Sanofi stops the phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy because of insufficient likelihood of efficacy, with no safety signals reported.

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

Jinsy A. Andrews, MD, Director of the ALS Clinic and Director of Clinical Trials at NYU Langone Health, discussed the evolving ALS treatment landscape, including emerging gene-targeted therapies, and the next generation of disease biomarkers.

Daniel Vitt, PhD, chief executive officer of Immunic, discussed the dual mechanism of vidofludimus calcium, ongoing phase 3 ENSURE trials in relapsing MS, and phase 2 CALLIPER findings suggesting potential neuroprotective effects in progressive MS.

Characterization of early-start TRAILBLAZER-ALZ 2 participants who required continued donanemab in the long-term extension suggests durable clinical benefit with fewer cumulative doses.

The professor at MedStar Georgetown University Hospital spoke about a live session that featured patient evaluations and injection demonstrations designed to help clinicians refine treatment strategies for dystonia, spasticity, sialorrhea, and other neurologic conditions. [WATCH TIME: 2 minutes]

Early data from the Clinical Nurse Navigator program show that more than 99% of patients with Parkinson's disease reaching a first optimization dose of continuous subcutaneous apomorphine infusion did so without antiemetic pretreatment.